In The Media
Capitol Street’s health policy experts regularly contribute in leading national and healthcare media, as well as industry conferences and events.
Recent Media & Events
Manufacturer & Plan Impact of the Medicaid PBM and Drug Rule
May 24, 2023
Smolinski interviewed about the CMS proposal about a Medicaid drug price name and shame policy. CMS has proposed a new Medicaid rule aimed at increasing transparency around some drug prices and PBM practices. Under the proposal, Medicaid would not be given power over drug prices. Rather, it would create what Capitol Street consultants call a “Medicaid Rx wall of shame” on which it would post the prices of three to 10 drugs Medicaid believes have abnormally high prices or have been subject to large price increases. PBMs would be forced to disclose the prices they pay for drugs to their Medicaid clients.
JP Morgan keynote discussion with FDA Commissioner Califf and ARPA-H Director Wegrzyn
January 10, 2023
For the Jan. 10 lunchtime keynote at the JP Morgan Healthcare Conference, Ipsita Smolinski of Capitol Street and Rachel Vatnsdal of JP Morgan co-host a discussion with FDA Commissioner Robert Califf and ARPA-H Director Renee Wegrzyn about the Biden Administration’s 2023 priorities for Life Sciences, BioPharma and MedTech.
Implications of the Midterm Elections for Health Care Policy
November 30, 2022
Smolinski discussed upcoming priorities for the lame-duck session of the 117th Congress, implications for the 118th Congress, and priorities for the Biden Administration.
Smolinski hosts panel at annual AVBCC conference on October 19, 2022
Senate Democrats pass sweeping healthcare, tax and climate bill
August 7, 2022
Smolinski provides biopharmaceutical business impact of CPI (inflationary) Rebate policy in the Inflation Reduction Act of 2022.
In a massive victory for Democrats, Medicare is poised to negotiate drug prices
August 7, 2022
Smolinski provides market perspective on the Medicare drug negotiation provision of the Inflation Reduction Act.
U.S. Elections May Thwart Democratic Effort to Cap Insulin Cost
May 6, 2022
Smolinski interviewed about prospects for lawmakers’ attempts to cut the cost of insulin to $35 per month.
Big Pharma Quietly Pushes Back on Global Tax Deal, Citing Covid-19 Role
July 27, 2021
Smolinski interviewed for WSJ article about U.S. tax policy and its effect on pharmaceutical companies in light of European countries’ push to harmonize minimum corporate tax rates.
Planning for Fiscal Strength in Changing Times
July 23, 2021
During a June 23 virtual event presented by Allscripts and Modern Healthcare Custom Media, Ipsita Smolinski, Managing Partner of Capitol Street Research and Senior Strategic Adviser at McAllister & Quinn, and Richard Mulry, President and CEO of Northwell Holdings and Ventures, offered insights into and guidance specific to where hospital systems should be prioritizing as they do strategic planning, during a COVID time of health equity and physician employment along with increasing transparency rules for health systems, looking ahead to the next several years.
FDA’s expansive Alzheimer’s drug approval surprised even top agency officials
July 8, 2021
Smolinski interviewed for a STAT News article about the FDA’s June 2021 approval of Aduhelm as a treatment for Alzheimer’s disease using the accelerated approval pathway.
Pelosi drug price plan threatened by centrist defections
May 11, 2021
Smolinski interviewed about the prospects for meaningful drug pricing legislation under slim Democratic margins in the House.
Biden called for drug pricing reform this year. But it’s an empty call.
April 28, 2021
Early in his term, President Biden pushes for Medicare to negotiate drug prices. Smolinski interviewed by STAT News on his plan and prospects.
BIO Conference Panel: Investors' Reactions to Reference Pricing Models
February 17, 2021
Smolinski participates in panel discussion at the BIO 2021 CEO & Investor Conference with Peter Kolchinsky (Partner, RA Capital) to discuss reference drug pricing — Most Favored Nation and International Price Indexing — and capital markets’ reactions and expectations.
